Neoadjuvant Therapy in Oscc (2026-04)

Compiled: April 28, 2026
For: Dr. Liming Gou, Oral and Maxillofacial Surgeon
Research Type: Multi-Agent Deep Research Investigation

Executive Summary

Your observation is correct — neoadjuvant immunotherapy outcomes are indeed impressive. This review synthesizes the latest evidence on:

  1. Effectiveness of neoadjuvant chemotherapy vs immunotherapy
  2. Indications and patient selection criteria
  3. Timing of surgery after treatment
  4. Surgical resection planning after tumor shrinkage

1. EFFECTIVENESS COMPARISON

Neoadjuvant Chemotherapy (NAC)

Key Finding: No Proven Survival Benefit

Outcome NAC + Surgery Surgery Alone Evidence Level
5-year OS 45-55% 42-52% Meta-analyses (non-significant)
ORR (TPF regimen) 68-80% — Phase III trials
pCR rate 15-25% — Multiple studies

Critical Evidence:

  • MACH-NC meta-analysis (87 RCTs, 16,485 patients): No OS benefit for neoadjuvant chemotherapy in OSCC specifically
  • Oral cavity cancers showed less benefit than oropharyngeal cancers
  • NCCN/NCI: NAC is NOT standard of care for OSCC — should only be offered in clinical trials

If NAC is used:

  • TPF regimen (docetaxel + cisplatin + 5-FU) superior to PF
  • TPF vs PF: HR 0.72 for OS (95% CI: 0.60-0.86)
  • Major toxicity: 76% neutropenia rate with TPF

Neoadjuvant Immunotherapy (NICT)

Key Finding: Impressive Results — Practice Changing

Trial Agent(s) MPR Rate pCR Rate 18-month OS
ChiCTR2200066119 Camrelizumab + Chemo 69% 41.4% 97%
NCT04826679 Camrelizumab + Chemo 63% 55.6% —
NeoRTPC02 Tislelizumab + RT + Chemo 82.6%* 60.9% —
NCT04393506 Camrelizumab + Apatinib 40% — 95%
IMCISION (Combo) Nivolumab + Ipilimumab 35% — —

*MPR+pCR combined

KEYNOTE-689: Practice-Changing Phase III Trial

First positive Phase III trial of perioperative immunotherapy in HNSCC

Parameter Result
Population 714 patients, stage III-IVA HNSCC
Treatment 2 neoadjuvant + 15 adjuvant cycles pembrolizumab
PD-L1 CPS ≥10 36-month EFS: 59.8% vs 45.9% (HR 0.66, p=0.004)
Surgery completion 88% (not compromised by immunotherapy)
Primary site >60% oral cavity

Why Immunotherapy Outperforms Chemotherapy

  1. Higher response rates: MPR 35-69% vs <20% with chemo alone
  2. Durable responses: Ongoing immune surveillance
  3. Lower recurrence in responders
  4. Better toxicity profile: Grade 3-4 AEs 4-38% (vs 76% neutropenia with TPF)
  5. No compromise of surgical options: No significant surgical delays

2. INDICATIONS AND PATIENT SELECTION

Current Guidelines Position

Guideline NAC Neoadjuvant Immunotherapy
NCCN 2024 Not routine; clinical trials only Under evaluation
NCI PDQ Not routine; no proven survival benefit Emerging evidence
ESMO Clinical trials only Not yet standard

Ideal Candidates for Neoadjuvant Immunotherapy

Tumor Characteristics

  • Stage III-IVA (T1-2N1-2M0 or T3-4aN0-2M0)
  • Locally advanced resectable disease
  • Borderline resectable tumors (where downsizing may help)
  • No distant metastases

Patient Characteristics

  • ECOG 0-1
  • Adequate organ function
  • No active autoimmune disease
  • No prior ≥Grade 3 irAEs
  • No untreated HBV/HCV

PD-L1 Thresholds

CPS Score Clinical Significance
CPS ≥20 Strongest benefit (100% MPR in one trial)
CPS ≥1 Benefit demonstrated (85% of patients)
CPS <1 Consider chemo-immunotherapy combo

Active Clinical Trials

  1. NEOPCOSCC (NCT05798793) — Phase III

    • Camrelizumab + TP chemo vs TP alone vs upfront surgery
    • 309 patients, recruiting

  2. KEYNOTE-689 — Phase III (positive results)

    • Establishing new standard

3. TIMING OF SURGERY

Critical Finding: The 28-Day Rule

Optimal Timing Window

Parameter Recommendation Evidence
Minimum interval ≥28 days (4 weeks) Chen 2026 (692 patients)
Optimal window 4-6 weeks (28-42 days) Multiple studies
Maximum interval 6-8 weeks Zhu 2024: >40 days = worse outcomes

Risk of Short Interval (<28 days)

Chen et al. 2026 (Front Immunol, PMID: 41836399):

  • Independent risk factor for major wound complications
  • Poor pathological response + short interval = highest complication risk

Impact on Complications

Group Major Wound Complications
NICT 9.2%
NAC alone 17.8%
Upfront surgery 21.5%

Key finding: NICT actually REDUCED complications vs NAC or upfront surgery!

irAEs and Surgery Delays

Most Common Reasons for Delay

irAE Type Frequency Impact on Surgery
Thyroid dysfunction 19.5% May need hormone replacement
Adrenal insufficiency 1.2% Critical — stress-dose steroids needed
Pneumonitis Rare but serious Can be fatal — postpone surgery
Hepatic toxicity Variable Wait for resolution

Surgery Delay Statistics (Lee 2026)

  • 7.3% of surgeries postponed due to irAEs
  • Mean delay: 64.5 days
  • Endocrine irAEs caused 50% of delays

Pre-Operative Checklist

  • CBC, metabolic panel
  • Thyroid function tests (TSH)
  • Morning cortisol if symptomatic
  • Chest imaging (rule out pneumonitis)
  • Review all irAEs and treatments
  • Steroid taper completed or at maintenance
  • Plan stress-dose steroids if on chronic steroids

4. SURGICAL RESECTION AFTER TUMOR SHRINKAGE

Key Question: Pre-treatment or Post-treatment Boundaries?

Current Evidence Supports POST-TREATMENT Boundaries

However, there are important caveats:

  1. Regression may be non-centripetal — scattered microscopic foci may remain beyond shrunken macroscopic tumor
  2. Integrated radiologic-pathologic planning is essential
  3. Do not reflexively narrow margins based solely on clinical shrinkage

Response-Adapted Surgery Outcomes

Outcome Result
Flap reconstruction avoided 72.1%
Planned mandibulectomies spared 70.8%
OS vs upfront surgery No significant difference (p=0.825)
DFS vs upfront surgery No significant difference (p=0.473)

Margin Assessment After Neoadjuvant Therapy

Traditional Margins (May Be Inadequate)

Classification Definition
Clear (R0) >5mm from tumor
Close 1-5mm
Positive (R1/R2) <1mm

New Biological Margin Index (MRIx)

Integrates 4 domains for risk stratification:

Domain Weight Low Risk Criteria
Histopathologic (TLS density) 30% TLS ≥3/mm²
Tumor Burden (Pan-CK+, Ki-67) 25% No Pan-CK+, Ki-67 <5%
Molecular (mutations, PD-L1) 25% No driver mutations
Immune Contexture 20% CD8+/FoxP3+ ratio ≥2

Risk Categories:

  • Low (0-0.8): Consider de-escalation
  • Intermediate (0.9-1.4): Standard adjuvant therapy
  • High (1.5-2.0): Treatment intensification

Any margin ≤2mm = automatic high-risk

Imaging for Surgical Planning

Modality Role
MRI Primary for tumor extent; habitat imaging predicts pCR (AUC ~0.90)
PET-CT Metabolic assessment, nodal staging, distant mets
PET-MRI fusion Superior for treatment response prediction

Management by Response Category

Response Definition Management
pCR 0% viable tumor Response-adapted surgery, consider de-escalation
MPR ≤10% viable tumor Reduced resection based on post-treatment boundaries
Partial 10-90% viable tumor Standard surgery + adjuvant based on margins
No Response >90% viable tumor Standard surgery + aggressive adjuvant therapy

5. KEY CLINICAL TAKEAWAYS

For Your Practice

  1. Neoadjuvant chemotherapy — NOT recommended for OSCC outside clinical trials (no proven survival benefit)

  2. Neoadjuvant immunotherapy — Impressive results (69% MPR, 97% 18-month OS in some trials). KEYNOTE-689 is practice-changing.

  3. Timing — Wait minimum 28 days, optimal 4-6 weeks, maximum 8 weeks. Shorter intervals increase complications.

  4. Surgical planning — Use post-treatment boundaries but beware non-centripetal regression. Consider MRIx for biological margin assessment.

  5. PD-L1 testing — CPS ≥10 predicts excellent response; CPS ≥1 benefits most patients.

Recommended Workflow

Locally Advanced OSCC (Stage III-IVA)
           ↓
    Multidisciplinary Discussion
           ↓
    PD-L1 Testing + Imaging Staging
           ↓
    If CPS ≥1, ECOG 0-1, no contraindications
           ↓
    Consider Neoadjuvant Immunotherapy (clinical trial preferred)
           ↓
    2-3 cycles (4-6 weeks)
           ↓
    Restaging MRI + PET-CT
           ↓
    Surgery at 4-6 weeks post-treatment
           ↓
    Pathologic Response Assessment
           ↓
    Adjuvant therapy based on margins and response

References

Key Clinical Trials

  1. KEYNOTE-689 — PMID: 41810147
  2. Xiang Z et al. 2025 (ChiCTR2200066119) — Nat Commun. PMID: 40295492
  3. Xu N et al. 2026 (MRIx development) — Front Immunol. PMID: 41727460
  4. Chen H et al. 2026 (Timing complications) — Front Immunol. PMID: 41836399
  5. Yin M et al. 2026 (NICT safety) — J Craniomaxillofac Surg. PMID: 41889040

Guidelines

  • NCCN Head and Neck Cancers Guidelines 2024
  • NCI PDQ Lip and Oral Cavity Cancer Treatment
  • ESMO Head and Neck Cancer Guidelines

Research compiled using multi-agent deep research methodology, April 2026

Source Registry: Neoadjuvant Therapy in OSCC

Research Conducted April 28, 2026

Peer-Reviewed Articles

Effectiveness & Outcomes

PMID First Author Title Journal Year URL
19446902 Pignon JP MACH-NC meta-analysis Radiother Oncol 2009 https://pubmed.ncbi.nlm.nih.gov/19446902/
33515668 Lacas B MACH-NC updated meta-analysis Radiother Oncol 2021 https://pubmed.ncbi.nlm.nih.gov/33515668/
21684027 Blanchard P Induction chemotherapy meta-analysis (MACH-CH) Radiother Oncol 2011 https://pubmed.ncbi.nlm.nih.gov/21684027/

Neoadjuvant Immunotherapy Trials

PMID First Author Title Journal Year URL
— Ju W-T Camrelizumab + Apatinib neoadjuvant (NCT04393506) Nat Commun 2022 https://www.nature.com/articles/s41467-022-33080-8
— Vos JL IMCISION: Nivolumab ± Ipilimumab (NCT03003637) Nat Commun 2021 https://www.nature.com/articles/s41467-021-26472-9
— Wu D Camrelizumab + Nab-paclitaxel + Cisplatin (NCT04826679) Nat Commun 2024 https://www.nature.com/articles/s41467-024-46444-z
— Wei Z-G neoCHANCE-1: Tislelizumab + Afatinib Nat Commun 2025 https://www.nature.com/articles/s41467-025-63978-y
— Liu Z NeoRTPC02: Tislelizumab + RT + Chemo Nat Commun 2025 https://www.nature.com/articles/s41467-025-59865-1
40295492 Xiang Z Camrelizumab + Chemo for LA-OSCC (ChiCTR2200066119) Nat Commun 2025 https://pubmed.ncbi.nlm.nih.gov/40295492/
41810147 — KEYNOTE-689 Phase III results Lancet Reg Health Southeast Asia 2026 https://pubmed.ncbi.nlm.nih.gov/41810147/

Timing of Surgery

PMID First Author Title Journal Year URL
41836399 Chen H Treatment-surgery interval complications in OSCC Front Immunol 2026 https://pubmed.ncbi.nlm.nih.gov/41836399/
41889040 Yin M NICT does not increase surgical complications J Craniomaxillofac Surg 2026 https://pubmed.ncbi.nlm.nih.gov/41889040/
41899525 Lee J irAEs and surgery delays Cancers 2026 https://pubmed.ncbi.nlm.nih.gov/41899525/
39585339 Mastrolonardo EV Response-adaptive surgical timing Clin Cancer Res 2025 https://pubmed.ncbi.nlm.nih.gov/39585339/
38366691 Zhu KX IC-RT timing >40 days worse outcomes Head Neck 2024 https://pubmed.ncbi.nlm.nih.gov/38366691/
41739398 Kuemmel S KEYNOTE-522 timing data Ann Surg Oncol 2026 https://pubmed.ncbi.nlm.nih.gov/41739398/
41940046 Osako T Fatal ILD after neoadjuvant nivolumab (case report) Surg Case Rep 2026 https://pubmed.ncbi.nlm.nih.gov/41940046/

Surgical Margins & Resection Planning

PMID First Author Title Journal Year URL
41727460 Xu N Margin Risk Index (MRIx) Front Immunol 2026 https://pubmed.ncbi.nlm.nih.gov/41727460/
41515542 Kowalski LP Precision surgery with biomarkers Diagnostics 2025 https://pubmed.ncbi.nlm.nih.gov/41515542/
39889711 Liu HM Neoadjuvant IO ± Chemo randomized phase 2 Cell Rep Med 2025 https://pubmed.ncbi.nlm.nih.gov/39889711/
41727640 Seng H Optimal timing of surgery after NAIC Front Oncol 2026 https://pubmed.ncbi.nlm.nih.gov/41727640/
41532448 Zhao TC Emerging role of neoadjuvant IO in OSCC Int J Surg 2026 https://pubmed.ncbi.nlm.nih.gov/41532448/
41504501 Ye Z NAIC regimens systematic review Int J Surg 2026 https://pubmed.ncbi.nlm.nih.gov/41504501/
41701314 — DEGRO Statement on KEYNOTE-689 Strahlenther Onkol 2026 https://pubmed.ncbi.nlm.nih.gov/41701314/
41899621 Di Mauro A Modern pathology-driven strategies Cancers 2026 https://pubmed.ncbi.nlm.nih.gov/41899621/
38727853 Tanaka PCE regimen for HNSCC Int J Clin Oncol 2024 https://pubmed.ncbi.nlm.nih.gov/38727853/
41450282 Vuppala Neoadjuvant vs adjuvant IO outcomes Head Neck 2025 https://pubmed.ncbi.nlm.nih.gov/41450282/

Clinical Trials

Trial ID Title URL Status Accessed
NCT05798793 NEOPCOSCC Phase III – Camrelizumab + TP vs TP vs Surgery https://clinicaltrials.gov/study/NCT05798793 Recruiting 2026-04-28
NCT04393506 Camrelizumab + Apatinib neoadjuvant https://clinicaltrials.gov/study/NCT04393506 Completed 2026-04-28
NCT03003637 IMCISION – Nivolumab ± Ipilimumab https://clinicaltrials.gov/study/NCT03003637 Completed 2026-04-28
NCT04826679 Camrelizumab + Chemo neoadjuvant https://clinicaltrials.gov/study/NCT04826679 Completed 2026-04-28
NCT05517330 neoCHANCE-1 – Tislelizumab + Afatinib https://clinicaltrials.gov/study/NCT05517330 Completed 2026-04-28
NCT05343325 NeoRTPC02 – Tislelizumab + RT + Chemo https://clinicaltrials.gov/study/NCT05343325 Completed 2026-04-28
NCT03635432 Nivolumab + Ipilimumab neoadjuvant https://clinicaltrials.gov/study/NCT03635432 Completed 2026-04-28

Guidelines & Official Sources

Source Title URL Version/Date
NCI PDQ Lip and Oral Cavity Cancer Treatment (Health Professional Version) https://www.cancer.gov/types/head-and-neck/hp/adult/lip-mouth-treatment-pdq Updated May 14, 2025
NCCN Head and Neck Cancers Guidelines https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf 2024 (login required)
ESMO Head and Neck Cancer Clinical Practice Guidelines https://www.esmo.org/guidelines/esmo-clinical-practice-guidelines-head-and-neck-cancers Current

Review Articles & Summaries

Source Title URL
Nature Reviews Clinical Oncology KEYNOTE-689 Research Highlight https://www.nature.com/articles/s41571-025-01057-3
Nature Reviews Clinical Oncology Neoadjuvant immunotherapy review (Zhao M et al.) https://www.nature.com/articles/s41571-024-00969-w
Wikipedia Head and Neck Cancer (used for background) https://en.wikipedia.org/wiki/Head_and_neck_cancer
Wikipedia Oral Cancer (used for background) https://en.wikipedia.org/wiki/Oral_cancer

Verification Notes

Sources to Verify (Priority)

These are the key sources that support major claims — please verify:

  1. PMID 41836399 (Chen 2026) — Critical claim about <28 day interval risk

  2. PMID 40295492 (Xiang 2025) — ChiCTR2200066119 69% MPR, 97% OS

  3. PMID 41810147 (KEYNOTE-689) — Phase III results

  4. PMID 41727460 (Xu 2026) — MRIx biological margin index

  5. PMID 41889040 (Yin 2026) — NICT safety vs upfront surgery

Nature Communications Articles

Several trials were published in Nature Communications without PMIDs listed. Verify via DOI:

ClinicalTrials.gov

All trial IDs listed can be verified at:

Known Limitations

  1. Future dates: Some PMIDs show 2026 publication dates. These may be:

    • Advanced online publications
    • If not found, may be hallucinated — please verify

  2. Nature Communications articles: Some lacked PMIDs in the source material — verify via DOI

  3. Guidelines: NCCN and ESMO require login for full access

Registry compiled: April 28, 2026
Total sources: 25+ peer-reviewed articles, 7 clinical trials, 3 guidelines